Abstract
Immunotherapy is the basic therapeutic approach for patients with metastatic malignant melanoma. This therapy improves overal survival and might achieve long lasting complete remissions of stabilizations.
Today we can use anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab, pembrolizumab) antibodies. The following case report describes patient treated with pembrolizumab for metastatic melanoma in the third line with long-term partial regression.
The case report also points out the possible pitfalls of this therapy in the form of specific side effects that may be a reason for discontinuation of therapy-